[Express Train - Episode 81] PCL, Game Changer in the Diagnostic Platform Market

PCL has succeeded in clinical trials for high-risk viruses and multiplex diagnostics for the first time in the world, based on its proprietary 3D SG Cap™ ultra-sensitivity technology. Utilizing its ultra-sensitivity, low-cost, and high-efficiency multiplex diagnostic platform technology, it is developing and supplying blood screening diagnostic products.

Patent attorney Um Jeong-han from BLT Patent Law Office reviewed PCL's patent and trademark application status.

Listed companies on the domestic stock market disclose patent acquisition information through the Financial Supervisory Service's electronic disclosure system. However, many stock investors tend to overlook patent disclosures.

Not only patents but also trademark registrations serve as important indicators for understanding future corporate value, as they signal the direction a listed company is heading. Some patent disclosures even act as direct triggers for stock price increases.

It is not easy for general investors to assess the impact on companies through patent disclosures or to check trademark application statuses one by one. Asia Economy, together with patent attorney Um Jeong-han from BLT Patent Law Office, is reviewing the patent and trademark application statuses of listed companies through the 'Express Train' series.

'Express Train' is an abbreviation for a broadcast that diligently searches for stocks surging due to patents.